NEW YORK––Pfizer Animal Health introduces a vaccine that takes reproductive protection to the next level. The newly released Bovi-Shield GOLD HB combines five-way viral protection with the prevention of Leptospira borgpetersenii serovar Hardjo type Hardjo-bovis, commonly known as Lepto hardjo-bovis.
Lepto hardjo-bovis is the most prevalent strain of leptospira in U.S. cowherds. A recent study found 42% of beef herds infected. A previously reported study suggested 59% of U.S. dairy herds may be infected with leptospira.Lepto hardjo-bovis may cause poor reproductive performance, early embryonic death, delayed breeding, abortions, weak or stillborn calves and unexplained infertility.
“Lepto hardjo-bovis is an insidious reproductive problem,” says Glenn Rogers, Pfizer Animal Health veterinarian. “It doesn’t typically cause a dramatic drop in pregnancy rates or an abortion storm that is sometimes associated with leptospirosis. It moves quietly into a herd and over time takes a toll on its reproductive efficiency.”
Bovi-Shield GOLD HB provides superior protection against five major viral pathogens: IBR, PI3, BRSV and BVD Types 1 and 2. Combine that with the prevention of infection label claim for Lepto hardjo-bovis, and Bovi-Shield GOLD HB offers producers convenience and flexibility with one vaccine that can be administered intramuscularly or subcutaneously.
Bovi-Shield GOLD HB offers unmatched duration of immunity versus competitive reproductive vaccines, with at least 365 days of immunity for IBR abortions, BVD Types 1 and 2 persistent infection, Lepto hardjo-bovis infection, and Lepto hardjo-bovis urinary shedding and kidney colonization.
For a Lepto hardjo-bovis fact sheet, click here. For more information on Bovi-Shield GOLD HB, go to www.bovishieldgold.com or contact your local veterinarian, animal health supplier or Pfizer Animal Health representative.
